Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 09:14 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the...
December 10, 2025 09:28 ET | Source: Precedence Research

3D Printing Materials Market Size to Worth USD 31.23 Billion by 2035 - Exclusive Report by Towards Chemical and Materials

The global 3D Printing Materials market is projected to grow from USD 4.66 billion in 2025 to USD 31.23 billion by 2035 at a CAGR of 20.96%
December 09, 2025 09:21 ET | Source: Janssen Cilag International NV

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years...
December 06, 2025 09:30 ET | Source: Janssen Cilag International NV

Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data...
December 05, 2025 07:38 ET | Source: Research and Markets

Bio-Implants Market Set for a $245 Billion Valuation by 2030: Advanced 3D Printing Revolutionizes Bio-Implants with Tailored Solutions for Enhanced Patient Outcomes

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Bio-Implants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering....
December 05, 2025 06:30 ET | Source: Research and Markets

$480+ Mn Rapid Liquid Printing Market - Global Forecasts from 2025 to 2030 Featuring Autodesk, Steelcase, 3D Systems, Materialise, BMW, MIT Self-Assembly Lab, Stratasys, EOS

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Rapid Liquid Printing Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Rapid Liquid Printing...
December 04, 2025 09:30 ET | Source: Custom Market Insights

[Latest] Global 4D Printing in Healthcare Market Size/Share Worth USD 14240 Million by 2034 at a 84.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “4D Printing in Healthcare Market Size, Trends and Insights By Component...
November 28, 2025 04:16 ET | Source: Research and Markets

North America 3D Printing in Healthcare Market Analysis Report 2025-2033 Featuring 3D Systems, Exone, Formlabs, General Electric, Materialise, Oxferd Performance Materials, and Organovo

Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The "North America 3D Printing in Healthcare Market Report by Offering, Technology, Application, Country and Company Analysis, 2025-2033" report has been...
November 26, 2025 01:05 ET | Source: CMB.TECH NV.

CMB.TECH announces Q3 2025 results

CMB.TECH ANNOUNCES Q3 2025 RESULTSSOFT SUMMER, FOLLOWED BY ROARING TANKER AND DRY BULK MARKETS ANTWERP, Belgium, 26 November 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT,...
November 17, 2025 02:30 ET | Source: LEXIBOOK

LEXIBOOK S1 2025-26 REVENUE: €30.4 million vs €24.6 million (+€5.8 million, +23.6%). OPERATING PROFIT DOWN TO €2.3 million (-€130,000 vs H1 24-25) DUE TO A 0.8-POINT DECREASE IN GROSS MARGIN, AN INCREASE IN PERSONNEL EXPENSES (+€1.0 million

LEXIBOOK S1 2025-26 REVENUE: €30.4 million vs €24.6 million (+€5.8 million, +23.6%). OPERATING PROFIT DOWN TO €2.3 million (-€130,000 vs H1 24-25) DUE TO A 0.8-POINT DECREASE IN GROSS MARGIN, AN...